Anti-hCD20-hIgG4 Unit size Cat. code Docs Qty Price
100 µg

Monoclonal human IgG4 antibody against human CD20

Anti-hCD20-hIgG4 features the constant region of the human IgG4 isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia. Anti-hCD20-hIgG4 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.


Back to the top


Clonality: Monoclonal antibody
Specificity: Targets cells expressing human CD20
Isotype: Human IgG4

Back to the top


100 µg purified anti-hCD20-hIgG4 antibody, provided azide-free and lyophilized

Back to the top

Customer Service
& Technical Support

In order to prevent automated spam submissions, please answer the following question:
5 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Shopping cart is empty